Trial Profile

A Phase 1 Trial of Naptumomab Estafenatox (NAP) in Combination With Pembrolizumab (Pembro) Preceded by Obinutuzumab (Obi) in Patients With Urothelial Cancers

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naptumomab estafenatox (Primary) ; Obinutuzumab (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Urethral cancer; Urogenital cancer
Focus Adverse reactions

Most Recent Events

11 Apr 2024 Planned End Date changed from 1 Jun 2028 to 1 Dec 2025.
11 Apr 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Nov 2023.
11 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com